Cell>Point closes Phase II part of Phase II/III trial

06/28/2010 | Business Wire

In light of encouraging results, Cell>Point said it has closed the Phase II part of its Phase II/III study involving the use of 99mTc-EC-G in assessing the presence and reach of nonsmall-cell lung cancer in patients. As a next step, the company will submit a report to the FDA regarding the results of the Phase II study and discuss measures in conducting the Phase III part of the trial.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX